Biotech | April 05, 2022
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
It is currently available in tablet and injectable dosage forms
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
The symposium was organized by the Gut Microbiota and Probiotic Science Foundation (India) and Medanta Institute of Education and Research, Gurugram, and Amity University, Gurugram
The company inaugurated the new production line at the Bengaluru facility to manufacture Computed Tomography Scanners
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
It is one of the 15 medical device manufacturers approved under the government’s PLI scheme
Through this consortium, Lonza will collaborate with other industry leaders to advance the research and development of inhalation technologies
Subscribe To Our Newsletter & Stay Updated
